

Datasheet: MCA1346F

| | |
|----------------------|-------------------------|
| Description: | MOUSE ANTI CAT CD4:FITC |
| Specificity: | CD4 |
| Format: | FITC |
| Product Type: | Monoclonal Antibody |
| Clone: | vpg34 |
| Isotype: | IgG1 |
| Quantity: | 0.1 mg |

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

| | Yes | No | Not Determined | Suggested Dilution |
|----------------|-----|----|----------------|--------------------|
| Flow Cytometry | ▪ | | | Neat - 1/10 |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

| | | | |
|---------------------------------------|--|----------------------------|--------------------------|
| Target Species | Cat | | |
| Product Form | Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid | | |
| Max Ex/Em | Fluorophore | Excitation Max (nm) | Emission Max (nm) |
| | FITC | 490 | 525 |
| Preparation | Antibody purified from tissue culture supernatant | | |
| Buffer Solution | Phosphate buffered saline | | |
| Preservative | 0.09% sodium azide (NaN ₃) | | |
| Stabilisers | 1% bovine serum albumin | | |
| Approx. Protein Concentrations | IgG concentration 0.1mg/ml | | |
| Immunogen | Immunoaffinity purified feline CD4. | | |

RRID AB_322909

Fusion Partners Spleen cells from immunized BALB/c were fused with cells of the NS0 mouse myeloma cell line.

Specificity **Mouse anti Cat CD4 antibody, clone vpg34** recognizes the feline homolog of the human CD4 antigen. CD4 is not expressed on feline monocytes.

Flow Cytometry Use 10µl of the suggested working dilution to label 10⁶ lymphocytes in 100µl

- References**
1. Calmann, J.J. *et al.* (1993) Morphologic Characterization of the Lymph Node Changes in Feline Immunodeficiency Virus Infection as an Animal Model of AIDS1 [In: Racz P, Letvin NL, Gluckman JC \(eds\): Animal Models of HIV and Other Retroviral Infections. Basel, Karger, 1993. pp 115-136](#)
 2. Willett, B.J. *et al.* (1994) The generation of monoclonal antibodies recognising novel epitopes by immunisation with solid matrix antigen-antibody complexes reveals a polymorphic determinant on feline CD4. [J Immunol Methods. 176 \(2\): 213-20.](#)
 3. Hosie, M.J. *et al.* (2000) Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. [J Virol. 74: 9403-11.](#)
 4. Hosie, M.J. *et al.* (2002) Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence. [J Virol. 76: 6062-72.](#)
 5. Flynn, J.N. *et al.* (2002) Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection. [J Virol. 76: 2306-15.](#)
 6. Campbell, D.J. *et al.* (2004) Insulin-like growth factor-I (IGF-I) and its association with lymphocyte homeostasis in the ageing cat. [Mech Ageing Dev. 125: 497-505.](#)
 7. Campbell, D.J. *et al.* (2004) Age-related differences in parameters of feline immune status. [Vet Immunol Immunopathol. 100: 73-80.](#)
 8. Milner, R.J. *et al.* (2004) Suppurative rhinitis associated with *Haemophilus* species infection in a cat. [J S Afr Vet Assoc. 75: 103-7.](#)
 9. Webb, C. *et al.* (2006) Use of flow cytometry and monochlorobimane to quantitate intracellular glutathione concentrations in feline leukocytes. [Vet Immunol Immunopathol. 112 \(3-4\): 129-40.](#)
 10. Veir, J.K. *et al.* (2006) Evaluation of a novel immunotherapy for treatment of chronic rhinitis in cats. [J Feline Med Surg. 8 \(6\): 400-11.](#)
 11. Willett, B.J. *et al.* (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. [J Virol. 81: 9665-79.](#)
 12. Avery, P.R. *et al.* (2007) Sustained generation of tissue dendritic cells from cats using organ stromal cell cultures. [Vet Immunol Immunopathol. 117 \(3-4\): 222-35.](#)
 13. Veir, J.K. *et al.* (2007) Effect of supplementation with *Enterococcus faecium* (SF68) on immune functions in cats. [Vet Ther. 8: 229-38.](#)
 14. Webb, C. *et al.* (2008) Oxidative stress during acute FIV infection in cats. [Vet Immunol Immunopathol. 122 \(1-2\): 16-24.](#)
 15. Carreño, A.D. *et al.* (2008) Loss of naïve (CD45RA+) CD4+ lymphocytes during pediatric infection with feline immunodeficiency virus. [Vet Immunol Immunopathol. 121: 161-8.](#)
 16. Freer, G. *et al.* (2008) Immunotherapy with internally inactivated virus loaded dendritic

- cells boosts cellular immunity but does not affect feline immunodeficiency virus infection course. [Retrovirology. 5: 33.](#)
17. Reinero, C.R. *et al.* (2008) Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. [Vet Immunol Immunopathol. 121: 241-50.](#)
18. Reche, A.Jr. *et al.* (2010) Cutaneous mycoflora and CD4:CD8 ratio of cats infected with feline immunodeficiency virus. [J Feline Med Surg. 12: 355-8.](#)
19. Kraase, M. *et al.* (2010) Feline immunodeficiency virus env gene evolution in experimentally infected cats. [Vet Immunol Immunopathol. 134: 96-106.](#)
20. Pistello, M. *et al.* (2010) Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. [J Virol. 84: 3845-56.](#)
21. Novacco, M. *et al.* (2012) Protection from reinfection in "*Candidatus Mycoplasma turicensis*"-infected cats and characterization of the immune response. [Vet Res. 43: 82.](#)
22. Willett, B.J. *et al.* (2013) Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies. [PLoS One. 8: e54871.](#)
23. Baumann J *et al.* (2015) Lack of cross-protection against *Mycoplasma haemofelis* infection and signs of enhancement in "*Candidatus Mycoplasma turicensis*"-recovered cats. [Vet Res. 46: 104.](#)
24. McLuckie, A.J. *et al.* (2016) Detection of *Felis catus* gammaherpesvirus 1 (FcaGHV1) in peripheral blood B- and T-lymphocytes in asymptomatic, naturally-infected domestic cats. [Virology. 497: 211-6.](#)
25. Sugiarto, S. *et al.* (2016) Passive immunization does not provide protection against experimental infection with *Mycoplasma haemofelis*. [Vet Res. 47 \(1\): 79.](#)
26. MirandaL, H.M. *et al.* (2018) Co-infection with feline retrovirus is related to changes in immunological parameters of cats with sporotrichosis. [PLoS One. 13 \(11\): e0207644.](#)
27. Sieg, M. *et al.* (2019) A New Genotype of Feline Morbillivirus Infects Primary Cells of the Lung, Kidney, Brain and Peripheral Blood. [Viruses. 11 \(2\) Feb 09 \[Epub ahead of print\].](#)
28. Maeta, N. *et al.* (2019) Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats. [Open Vet J. 9 \(2\): 147-50.](#)
29. de Oliveira Matheus, L.F. *et al.* (2021) Effects of *Saccharomyces cerevisiae*. cell wall addition on feed digestibility, fecal fermentation and microbiota and immunological parameters in adult cats. [BMC Vet Res. 17 \(1\): 351.](#)
30. Rütgen, B.C. *et al.* (2022) Composition of lymphocyte subpopulations in normal and mildly reactive peripheral lymph nodes in cats. [J Feline Med Surg. 24 \(2\): 77-90.](#)
31. Cha, S. *et al.* (2023) Non-B, Non-T Acute Lymphoblastic Leukemia in a Cat [Journal of Veterinary Clinics. 40 \(4\): 298-302.](#)
32. R7uuml;tgen, B.C. *et al.* (2024) Flowcytometric data of intermediate-large cell gastrointestinal lymphoma presenting a gross mass in 32 cats – “let them glow in the flow” [Frontiers in Veterinary Science. 28 May \[Epub ahead of print\].](#)

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

| | |
|------------------|---------------------------------|
| Guarantee | 12 months from date of despatch |
|------------------|---------------------------------|

| | |
|--------------------------------------|--|
| Health And Safety Information | Material Safety Datasheet documentation #10041 available at: https://www.bio-rad-antibodies.com/SDS/MCA1346F 10041 |
|--------------------------------------|--|

| | |
|-------------------|----------------------------|
| Regulatory | For research purposes only |
|-------------------|----------------------------|

Related Products

Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL:FITC \(MCA928F\)](#)

[MOUSE IgG1 NEGATIVE CONTROL:FITC \(MCA1209F\)](#)

| | | | | | |
|----------------------------------|---|------------------|---|---------------|---|
| North & South America | Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com | Worldwide | Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com | Europe | Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com |
|----------------------------------|---|------------------|---|---------------|---|

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M410374:221028'

Printed on 30 May 2024